<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39375947</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Validation Assessment of Privacy-Preserving Synthetic Electronic Health Record Data: Comparison of Original Versus Synthetic Data on Real-World COVID-19 Vaccine Effectiveness.</ArticleTitle><Pagination><StartPage>e70019</StartPage><MedlinePgn>e70019</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70019</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To assess the validity of privacy-preserving synthetic data by comparing results from synthetic versus original EHR data analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A published retrospective cohort study on real-world effectiveness of COVID-19 vaccines by Maccabi Healthcare Services in Israel was replicated using synthetic data generated from the same source, and the results were compared between synthetic versus original datasets. The endpoints included COVID-19 infection, symptomatic COVID-19 infection and hospitalization due to infection and were also assessed in several demographic and clinical subgroups. In comparing synthetic versus original data estimates, several metrices were utilized: standardized mean differences (SMD), decision agreement, estimate agreement, confidence interval overlap, and Wald test. Synthetic data were generated five times to assess the stability of results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The distribution of demographic and clinical characteristics demonstrated very small difference (&lt; 0.01 SMD). In the comparison of vaccine effectiveness assessed in relative risk reduction between synthetic versus original data, there was a 100% decision agreement, 100% estimate agreement, and a high level of confidence interval overlap (88.7%-99.7%) in all five replicates across all subgroups. Similar findings were achieved in the assessment of vaccine effectiveness against symptomatic COVID-19 Infection. In the comparison of hazard ratios for COVID 19-related hospitalization and odds ratio for symptomatic COVID-19 Infection, the Wald tests suggested no significant difference between respective effect estimates in all five replicates for all patient subgroups but there were disagreements in estimate and decision metrices in some subgroups and replicates.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Overall, comparison of synthetic versus original real-world data demonstrated good validity and reliability. Transparency on the process to generate high fidelity synthetic data and assurances of patient privacy are warranted.</AbstractText><CopyrightInformation>© 2024 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Echo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Epidemiology, Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences (BARDS), Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mott</LastName><ForeName>Katrina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Epidemiology, Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences (BARDS), Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hongtao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences (BARDS), Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazit</LastName><ForeName>Sivan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Kahn Sagol Maccabi (KSM) Research &amp; Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chodick</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burcu</LastName><ForeName>Mehmet</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4572-0987</Identifier><AffiliationInfo><Affiliation>Epidemiology, Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Research Decision Sciences (BARDS), Merck &amp; Co., Inc., Rahway, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Merck &amp; Co., Inc., Rahway, NJ, United States</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="N">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018907" MajorTopicYN="N">Privacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data access</Keyword><Keyword MajorTopicYN="N">data validity/quality</Keyword><Keyword MajorTopicYN="N">patient privacy</Keyword><Keyword MajorTopicYN="N">real‐world data</Keyword><Keyword MajorTopicYN="N">real‐world evidence</Keyword><Keyword MajorTopicYN="N">replicability</Keyword><Keyword MajorTopicYN="N">synthetic data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>1</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375947</ArticleId><ArticleId IdType="doi">10.1002/pds.70019</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. Henriksen‐Bulmer and S. Jeary, “Re‐Identification Attacks—A Systematic Literature Review,” International Journal of Information Management 36 (2016): 1184–1192.</Citation></Reference><Reference><Citation>R. E. Foraker, S. C. Yu, A. Gupta, et al., “Spot the Difference: Comparing Results of Analyses From Real Patient Data and Synthetic Derivatives,” JAMIA Open 3, no. 4 (2020): 557–566.</Citation></Reference><Reference><Citation>G. M. Raab, B. Nowok, and C. Dibben, “Practical Data Synthesis for Large Samples,” Journal of Privacy and Confidentiality 7, no. 3 (2017): 67–97.</Citation></Reference><Reference><Citation>S. El Kababji, N. Mitsakakis, X. Fang, et al., “Can Synthetic Data Accurately Mimic Oncology Clinical Trials?,” (paper presented, American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, 2023).</Citation></Reference><Reference><Citation>P. Myles, J. Ordish, and A. Tucker, “The Potential Synergies Between Synthetic Data and Trials in Relation to Generating Representative Virtual Population Cohorts,” Progress in Biomedical Engineering 5 (2023): 013001, https://iopscience.iop.org/article/10.1088/2516‐1091/acafbf/pdf.</Citation></Reference><Reference><Citation>Z. Azizi, S. Lindner, Y. Shiba, et al., “A Comparison of Synthetic Data Generation and Federated Analysis for Enabling International Evaluations of Cardiovascular Health,” Scientific Reports 13, no. 1 (2023): 11540.</Citation></Reference><Reference><Citation>C. Alloza, B. Knox, H. Raad, et al., “A Case for Synthetic Data in Regulatory Decision‐Making in Europe,” Clinical Pharmacology and Therapeutics 114, no. 4 (2023): 795–801.</Citation></Reference><Reference><Citation>Sciences NCfAT, “N3C Data Overview,” 2024, https://ncats.nih.gov/research/research‐activities/n3c/data‐overview.</Citation></Reference><Reference><Citation>A. Prasanna, B. Jing, G. Plopper, et al., “Synthetic Health Data Can Augment Community Research Efforts to Better Inform the Public During Emerging Pandemics,” medRxiv, 2023.</Citation></Reference><Reference><Citation>J. A. Thomas, R. E. Foraker, N. Zamstein, et al., “Demonstrating an Approach for Evaluating Synthetic Geospatial and Temporal Epidemiologic Data Utility: Results From Analyzing &gt; 1.8 Million SARS‐CoV‐2 Tests in the United States National COVID Cohort Collaborative (N3C),” Journal of the American Medical Informatics Association 29, no. 8 (2022): 1350–1365.</Citation></Reference><Reference><Citation>R. Foraker, A. Guo, J. Thomas, et al., “The National COVID Cohort Collaborative: Analyses of Original and Computationally Derived Electronic Health Record Data,” Journal of Medical Internet Research 23, no. 10 (2021): e30697.</Citation></Reference><Reference><Citation>M. A. Haendel, C. G. Chute, T. D. Bennett, et al., “The National COVID Cohort Collaborative (N3C): Rationale, Design, Infrastructure, and Deployment,” Journal of the American Medical Informatics Association 28, no. 3 (2021): 427–443.</Citation></Reference><Reference><Citation>K. El Emam, L. Mosquera, X. Fang, and A. El‐Hussuna, “Utility Metrics for Evaluating Synthetic Health Data Generation Methods: Validation Study,” JMIR Medical Informatics 10, no. 4 (2022): e35734.</Citation></Reference><Reference><Citation>Z. Azizi, C. Zheng, L. Mosquera, L. Pilote, K. El Emam, and G.‐F. Collaborators, “Can Synthetic Data Be a Proxy for Real Clinical Trial Data? A Validation Study,” BMJ Open 11, no. 4 (2021): e043497.</Citation></Reference><Reference><Citation>A. Reiner Benaim, R. Almog, Y. Gorelik, et al., “Analyzing Medical Research Results Based on Synthetic Data and Their Relation to Real Data Results: Systematic Comparison From Five Observational Studies,” JMIR Medical Informatics 8, no. 2 (2020): e16492.</Citation></Reference><Reference><Citation>S. El Kababji, N. Mitsakakis, X. Fang, et al., “Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets,” JCO Clinical Cancer Informatics 7 (2023): e2300116.</Citation></Reference><Reference><Citation>G. Chodick, L. Tene, R. S. Rotem, et al., “The Effectiveness of the Two‐Dose BNT162b2 Vaccine: Analysis of Real‐World Data,” Clinical Infectious Diseases 74, no. 3 (2022): 472–478.</Citation></Reference><Reference><Citation>J. Cohen, Statistical Power Analysis for the Behavioral Sciences, 2nd ed. (Hillsdale, NJ: L. Erlbaum Associates, 1988).</Citation></Reference><Reference><Citation>L. Mosquera and K. El Emam, On the Validity of Statistical Analyses of Privacy‐Preserving Synthetic Data (ISPOR Webinar, 2022).</Citation></Reference><Reference><Citation>A. F. Karr, C. N. Kohnen, A. Oganian, J. P. Reiter, and A. P. Sanil, “A Framework for Evaluating the Utility of Data Altered to Protect Confidentiality,” American Statistician 60, no. 3 (2006): 224–232.</Citation></Reference><Reference><Citation>L. Mosquera, K. El Emam, L. Ding, et al., “A Method for Generating Synthetic Longitudinal Health Data,” BMC Medical Research Methodology 23, no. 1 (2023): 67.</Citation></Reference><Reference><Citation>E. R. H. Colin Mitchell, “Are Synthetic Health Data ‘Personal Data’?,” 2023.</Citation></Reference><Reference><Citation>K. El Emam, L. Mosquera, and X. Fang, “Validating a Membership Disclosure Metric for Synthetic Health Data,” JAMIA Open 5, no. 4 (2022): ooac083.</Citation></Reference><Reference><Citation>J. Chen, D. Chun, M. Patel, E. Chiang, and J. James, “The Validity of Synthetic Clinical Data: A Validation Study of a Leading Synthetic Data Generator (Synthea) Using Clinical Quality Measures,” BMC Medical Informatics and Decision Making 19, no. 1 (2019): 44.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>